ライフサイエンスコーパス: pulmonary

1 ns of neutrophils, causing susceptibility to pulmonary A. fumigatus infection.

2 polymorphisms, or concomitant drug intake on pulmonary ABCC1 activity.

3 = 0.006), whereas the opposite was true for pulmonary acute respiratory distress syndrome (p = 0.03)

4 Conclusion: PET with pulmonary administered (11)C-BMP can measure ABCC1 activ

5 iprofloxacin and where an equivalent dose of pulmonary-administered ciprofloxacin was ineffective.

6 Congenital pulmonary airway malformation volume ratio (CVR) measure

7 The pulmonary and cardiac standard uptake value and volume 1

8 Pulmonary and cardiovascular involvement were dominant p

9 se in humans of all ages and can affect both pulmonary and extrapulmonary sites.

10 ecommendations were formulated by a panel of pulmonary and sleep physicians, respiratory therapists,

11 tory cytokine in the at-risk for lung cancer pulmonary and the lung tumor microenvironments.

12 of, or treatment decision in cardiovascular, pulmonary, and metabolic diseases.

13 d no data have examined computed tomographic pulmonary angiography (CTPA) rates in subgroups at high

14 ing (VQ) or increased motion artifacts on CT pulmonary angiography (CTPA).

15 The role of dual energy computed tomographic pulmonary angiography (DECTPA) in revealing vasculopathy

16 Another 62-patient cohort who underwent CT pulmonary angiography before the first reported local CO

17 D-dimers on the day of CT pulmonary angiography had a predictive accuracy of 0.90

18 ditional patient with negative results at CT pulmonary angiography had deep venous thrombosis, thus r

19 The relative rate of CT pulmonary angiography positivity was recorded.

20 of CTEPH is provided by digital subtraction pulmonary angiography, preferably performed at a center

21 lly inducible vasculoprotective mechanism in pulmonary arterial and lung MV (microvascular) endotheli

22 No correlation was seen between pulmonary arterial blood flow and BPD outcomes.

23 artery-to-aorta (PA/AO) diameter ratio, and pulmonary arterial blood flow were determined.

24 telet-derived growth factor (PDGFB) in human pulmonary arterial endothelial (HPAE) cells.

25 higher in PAE cells isolated from idiopathic pulmonary arterial hypertension (IPAH) patients compared

26 Pulmonary arterial hypertension (PAH) is a fatal disease

27 Pulmonary arterial hypertension (PAH) is a lethal vascul

28 Pulmonary Arterial Hypertension (PAH) is overrepresented

29 and hemodynamic characteristics, response to pulmonary arterial hypertension (PAH)-approved drugs, an

30 is available on racial/ethnic differences in pulmonary arterial hypertension (PAH).Objectives: Determ

31 fib in RV fibrosis in human and experimental pulmonary arterial hypertension.

32 ary circulation, terlipressin decreased mean pulmonary arterial pressure (-6.5 +/- 1.8 mm Hg; p = 0.0

33 Pasco, Peru), a setting that increases both pulmonary arterial pressure and sympathetic outflow.

34 ental approach, we demonstrate that reducing pulmonary arterial pressure lowers basal MSNA in healthy

35 a steady reduction of right ventricular and pulmonary arterial pressures, toward normal levels of ri

36 significantly (P < .001) higher than in the pulmonary arteries (0.15 L/min +/- 0.10) and descending

37 nnels were abundantly expressed in the large pulmonary arteries (PAs) of healthy lung tissues from hu

38 zed by profound vascular remodeling in which pulmonary arteries narrow because of medial thickening a

39 ources, which may be either from systemic or pulmonary arteries or cardio-pulmonary fistulas.

40 Thrombosis of small and mid-sized pulmonary arteries was found in various degrees in all 1

41 Isolated pulmonary arteries were evaluated ex vivo in a myograph.

42 K channels in mesenteric arteries but not in pulmonary arteries, which may explain TRPV4(EC) -IK/SK c

43 present in the endothelium of mesenteric and pulmonary arteries.

44 ng in mesenteric arteries and its absence in pulmonary arteries.

45 /24), left ventricular aneurysms (n = 3/24), pulmonary arteriovenous malformations (AVMs) (n = 5/24),

46 Ms) (n = 5/24), and proximal interruption of pulmonary artery (n = 2/24).

47 y hemodynamic monitoring with an implantable pulmonary artery (PA) sensor is approved for patients wi

48 is study show that an 18 h exposure of human pulmonary artery endothelial cells to the different nano

49 Imaging guidelines do not accurately assess pulmonary artery occlusion pressure in ventilated critic

50 rade I diastolic dysfunction) had a measured pulmonary artery occlusion pressure less than 18 mm Hg.

51 iovascular Imaging guidelines, the predicted pulmonary artery occlusion pressure was indeterminate in

52 r Imaging guidelines for predicting elevated pulmonary artery occlusion pressure were both 74%.

53 Using the pulmonary artery occlusion technique, we sought to asses

54 Pulmonary artery occlusion waveform analysis with estima

55 POPH patients had mean pulmonary artery pressure >25 mm Hg, pulmonary vascular

56 ery mean gradient was 11 mm Hg, and systolic pulmonary artery pressure was 32 mm Hg.

57 ascular resistance >240 dyn-sec/cm(-5) , and pulmonary artery wedge pressure <=15 mm Hg without anoth

58 ft ventricular eccentricity index (EI), main pulmonary artery-to-aorta (PA/AO) diameter ratio, and pu

59 ing along the posterior surface of the right pulmonary artery.

60 Invasive pulmonary aspergillosis (IPA) is a significant cause of

61 ill UK patients with COVID-19 and suspected pulmonary aspergillosis.

62 ng was essential for host resistance against pulmonary Aspergillus fumigatus challenge through the re

63 n, suggesting that FSTL-1 influences type-17 pulmonary bacterial immunity.

64 We found that pulmonary but not systemic infection with a high-virulen

65 s in body size, blood pressure, and baseline pulmonary capillary wedge pressure between groups (eg, p

66 capillary wedge pressure between groups (eg, pulmonary capillary wedge pressure: LVH, 13.4+/-2.7 vers

67 or many diverse biological processes such as pulmonary/cardiovascular development and homeostasis.

68 s, which caused enhanced disease mediated by pulmonary CD8(+) T cell infiltration.

69 Effects of LAM on resident pulmonary cell types indicated recruitment and activatio

70 In the pulmonary circulation, terlipressin decreased mean pulmo

71 PAH was seen as a disease restricted to the pulmonary circulation.

72 yper-inflated, normo-, hypo- and non-aerated pulmonary compartments.

73 plications (OR, 1.36; 95% CI, 1.19 to 1.57), pulmonary complications (OR, 1.50; 95% CI, 1.29 to 1.74)

74 was associated with an increase in total and pulmonary complications and reoperation rate.

75 is that NETs may represent drivers of severe pulmonary complications of COVID-19 and suggest that NET

76 Pulmonary complications were only screened for in 19 asy

77 diography; however, whether exercise-induced pulmonary congestion carries prognostic implications is

78 arkedly accelerated MHV-68 pathology causing pulmonary consolidation and hemorrhage, increased mortal

79 We included 492 pulmonary CT angiograms (342 (69.9%) in patients with CO

80 s LPS-/IgG immune complexes-stimulated acute pulmonary damage through reducing vascular permeability

81 Intranasal instillation was used to achieve pulmonary delivery daily over 10 days to M. tuberculosis

82 e time of rhDNase in the lungs of mice after pulmonary delivery while preserving its full enzymatic a

83 ole in the clearance of those proteins after pulmonary delivery.

84 cardiac ejection fraction of less than 50%, pulmonary diffusion capacity of less than 80%, or a crea

85 (21,20.8%), diabetes (18,17.8%), and chronic pulmonary disease (16,15.8%) were the most common coexis

86 ion (6% versus 10%), and chronic obstructive pulmonary disease (4% versus 7%) in patients undergoing

87 (NIPPV) with outcomes in chronic obstructive pulmonary disease (COPD) and hypercapnia is uncertain.

88 ps such as patients with chronic obstructive pulmonary disease (COPD) are poorly understood.

89 UMEC/VI in patients with chronic obstructive pulmonary disease (COPD) at risk of future exacerbations

90 s receive a diagnosis of chronic obstructive pulmonary disease (COPD) each year, and it is the fourth

91 Rationale: Chronic obstructive pulmonary disease (COPD) exacerbations are prone to nonr

92 y viral infection causes chronic obstructive pulmonary disease (COPD) exacerbations.

93 und Pulmonary imaging of chronic obstructive pulmonary disease (COPD) has focused on CT or MRI measur

94 Chronic obstructive pulmonary disease (COPD) is a progressive condition of c

95 intolerance is common in chronic obstructive pulmonary disease (COPD) patients.

96 ades-long progression of chronic obstructive pulmonary disease (COPD) renders identifying different t

97 Rationale: Treatment of chronic obstructive pulmonary disease (COPD) with inhaled corticosteroids (I

98 le improved treatment of chronic obstructive pulmonary disease (COPD), asthma, or urinary incontinenc

99 d risk stratification in chronic obstructive pulmonary disease (COPD), but few large longitudinal coh

100 inished in patients with chronic obstructive pulmonary disease (COPD), with mounting evidence support

101 ding cystic fibrosis and chronic obstructive pulmonary disease (COPD).

102 l fibrillation (AF), and chronic obstructive pulmonary disease (COPD).

103 sociated with asthma and chronic obstructive pulmonary disease (COPD).

104 tia (n = 1036), and 3 of chronic obstructive pulmonary disease (n = 441).

105 primary lung infection, was more common than pulmonary disease alone.

106 Chronic pulmonary disease and gait abnormalities were more commo

107 moting recovery from critical illness due to pulmonary disease are foundational goals of the critical

108 ns in a heavy smoker and chronic obstructive pulmonary disease cohort, we confirmed the effects of PI

109 00 premature deaths from chronic obstructive pulmonary disease in the two countries.

110 ember 1), in determining chronic obstructive pulmonary disease risk and severity is controversial.Obj

111 algorithm was trained to output a measure of pulmonary disease severity on CXRs (pulmonary x-ray seve

112 Informing the Pathway of Chronic Obstructive Pulmonary Disease Treatment) trial demonstrated a signif

113 professionals who care for patients with NTM pulmonary disease, including specialists in infectious d

114 .69; p<0.001) for clinically defined chronic pulmonary disease, moderate-severe expiratory airflow li

115 , sleep apnea, diabetes, chronic obstructive pulmonary disease, previous myocardial infarction (MI),

116 Smoking also causes chronic obstructive pulmonary disease, which is treated with beta-adrenocept

117 sis, smear microscopy insufficiently detects pulmonary disease, with test result reporting taking lon

118 genesis, for example, in chronic obstructive pulmonary disease, yet the mechanisms that retain neutro

119 smokers with and without chronic obstructive pulmonary disease.

120 eases such as asthma and chronic obstructive pulmonary disease.

121 fungal pathogen capable of causing multiple pulmonary diseases, including invasive aspergillosis, ch

122 uding specialists in infectious diseases and pulmonary diseases.

123 le providing improved diagnosis of localized pulmonary diseases.

124 udy was to assess the impact of ABCC1 on the pulmonary disposition of 6-bromo-7-(11)C-methylpurine ((

125 ithelial barrier, where it may influence the pulmonary disposition of inhaled drugs and contribute to

126 tive bacterial respiratory culture predicted pulmonary dysfunction at discharge (odds ratio, 4.38; 95

127 Pulmonary dysfunction at discharge a priori defined as o

128 To characterize the mechanisms underlying pulmonary EGPA, we examined and compared EGPA paraffin-e

129 rapy include systemic fibrinolysis, surgical pulmonary embolectomy, and a growing number of options f

130 The composition of pulmonary emboli mirrored the most distal part of venous

131 Six patients with pulmonary embolism (46%) and 14 patients without pulmona

132 onary embolism (46%) and 14 patients without pulmonary embolism (52%) died at ICU discharge (odds rat

133 investigated rates of diagnostic testing for pulmonary embolism (PE) in US emergency departments (EDs

134 BEC in patients with acute intermediate-risk pulmonary embolism (PE).

135 endpoint of this study was the occurrence of pulmonary embolism according to the use of standard thro

136 modynamics were evaluated at baseline, after pulmonary embolism and after each dose by biventricular

137 Risk factors for pulmonary embolism in patients with coronavirus disease

138 omboembolism was not suspected before death; pulmonary embolism was the direct cause of death in 4 pa

139 ents are hemodynamically unstable with acute pulmonary embolism, and a minority of them have proximal

140 tion, thyrotoxicosis, alcohol, pericarditis, pulmonary embolism, and myocarditis).

141 hrombosis, two patients (15.4%) had isolated pulmonary embolism, and one patient (7.7%) had both cann

142 ich includes both deep venous thrombosis and pulmonary embolism, is a common and potentially fatal co

143 mbolism was defined as deep vein thrombosis, pulmonary embolism, or both, diagnosed greater than 24 h

144 st prognostication, cardiac arrest caused by pulmonary embolism, postresuscitation oxygenation and ve

145 be reasonably explained by a combination of pulmonary embolism, ventilation-perfusion mismatching in

146 ve accuracy of 0.90 (95% CIs: 0.78-1.00) for pulmonary embolism.

147 cannula-associated deep vein thrombosis and pulmonary embolism.

148 with and without contrast media to rule out pulmonary embolism.

149 ith COVID-19 have an increased prevalence of pulmonary embolisms (26%), and most (78.7%) have moderat

150 The location of pulmonary embolisms and the degree of elevation of D-dim

151 The prevalence of pulmonary embolisms was higher in patients with COVID-19

152 dicates that Notch3 signaling contributes to pulmonary emphysema in mgR mice.

153 e metabolic activity and morphology of human pulmonary endothelial cell monolayers.

154 we demonstrate a unique protective role for pulmonary endothelial HIF-2alpha and how decreased expre

155 programs spanning stem-like to regenerative pulmonary epithelial progenitor states.

156 increase influenza severity by damaging the pulmonary epithelial-endothelial barrier and increasing

157 rates of intravenous antibiotic use to treat pulmonary exacerbations.

158 Beside the commonly described pulmonary expression of the coronavirus disease 2019 (CO

159 apeutic strategy to prevent the irreversible pulmonary failure threatening the life of COVID-19 patie

160 Idiopathic pulmonary fibrosis (IPF) has a poor prognosis and limite

161 Idiopathic pulmonary fibrosis (IPF) is a disease with high 5-year m

162 Idiopathic pulmonary fibrosis (IPF) is a fatal disease of unknown c

163 Idiopathic pulmonary fibrosis (IPF) is characterized by exuberant d

164 in a mouse model of bleomycin (BLM)-induced pulmonary fibrosis by micro-CT, evaluating longitudinal

165 g tissues and fibroblasts from patients with pulmonary fibrosis compared to controls.

166 Idiopathic pulmonary fibrosis is a fatal disease involving destruct

167 In humans and mice, pulmonary fibrosis is associated with up-regulation of s

168 rders, which include dyskeratosis congenita, pulmonary fibrosis, and aplastic anemia, is characterize

169 onotype, and shift work) are associated with pulmonary fibrosis, making them risk factors.

170 inhibition of glutaminase 1 (GLS1) reverses pulmonary fibrosis.

171 patients and of mice upon bleomycin-induced pulmonary fibrosis.

172 were studied in the bleomycin mouse model of pulmonary fibrosis.

173 chronic fibroproliferative phase, leading to pulmonary fibrosis.

174 g, Mo-AM differentiation, and development of pulmonary fibrosis.

175 ncer, but also arthritis, heart diseases, or pulmonary fibrosis.

176 idase inhibitors attenuate bleomycin-induced pulmonary fibrosis.

177 nscription factor JUN is highly expressed in pulmonary fibrosis.

178 was well-tolerated, reduced the severity of pulmonary fibrotic lesions and extracellular matrix remo

179 The major pulmonary finding was diffuse alveolar damage in the acu

180 n cardiac vs infectious etiologies for their pulmonary findings.

181 rom systemic or pulmonary arteries or cardio-pulmonary fistulas.

182 ective of baseline peak O(2) consumption and pulmonary flow/systemic flow ratio.

183 oth prophylactic and therapeutic RDV improve pulmonary function and reduce lung viral loads and sever

184 enes, including RPS27L, were associated with pulmonary function deficits in obese children with asthm

185 xtracellular matrix remodeling, and improved pulmonary function in bleomycin-treated mice.

186 Prediction of postoperative pulmonary function in lung cancer patients before tumor

187 basis of a seven-category ordinal scale for pulmonary function on day 5.

188 Pulmonary function testing (PFT) is an important compone

189 STL-1 Hypo) mice underwent lung morphometry, pulmonary function testing, and micro-computed tomograph

190 ontrols, and the levels were correlated with pulmonary function.

191 anism might contribute to the improvement of pulmonary health and the prevention of adult respiratory

192 include the use of echo Doppler to estimate pulmonary hemodynamic measures, which may lead to miscla

193 ical surveillance for chronic thromboembolic pulmonary hypertension (CTEPH), with ventilation-perfusi

194 nts may develop hepatic encephalopathy (HE), pulmonary hypertension (PaHT), or liver tumors, among ot

195 However, persistent pulmonary hypertension (PH) after PEA remains a major de

196 isk for bronchopulmonary dysplasia (BPD) and pulmonary hypertension (PH) after preterm birth.

197 Rationale: Pulmonary hypertension (PH) associated with neurofibroma

198 Pulmonary hypertension (PH) is a feature of a variety of

199 Rationale: Pulmonary hypertension (PH) is a life-threatening cardio

200 rase-5 inhibitors (PDE5i) for groups 2 and 3 pulmonary hypertension (PH) is rising nationally, despit

201 remodeling of the pulmonary vasculature and pulmonary hypertension (PH).

202 erve lung structure and function and prevent pulmonary hypertension after intrauterine inflammation i

203 erves lung growth and function, and prevents pulmonary hypertension in a rat model of chorioamnioniti

204 sodilators are unlikely to benefit group 2/3 pulmonary hypertension patients and may cause harm.

205 ease in patients with chronic thromboembolic pulmonary hypertension undergoing PEA to predict postope

206 Such models of preclinical pulmonary hypertension, a disease of the pulmonary vascu

207 on, and risk stratification of patients with pulmonary hypertension.

208 pressure <=15 mm Hg without another cause of pulmonary hypertension.

209 outcome after PEA in chronic thromboembolic pulmonary hypertension.

210 train of C. neoformans significantly induced pulmonary IL-25 expression in the lungs but not brains.

211 Pulmonary illnesses related to e-cigarette use have been

212 Background Pulmonary imaging of chronic obstructive pulmonary disea

213 ivity and high specificity, NPV, and PPV for pulmonary IMI after HCT, particularly for non-Aspergillu

214 The pulmonary immune response protects healthy individuals a

215 These findings support a causal role of pulmonary impairment in lung cancer etiology.

216 ial proliferation and sustained M. abscessus pulmonary infection and permits evaluation of efficacies

217 The relationship of SARS-CoV-2 pulmonary infection and severity of disease is not fully

218 Key proportions of patients with findings of pulmonary infection and those requiring further inpatien

219 % (1925 of 1964 radiographs) and findings of pulmonary infection represented 2.0% (39 of 1964 radiogr

220 One death, due to atypical pulmonary infection, was assessed as possibly related to

221 a dual role for Pla in the initial stages of pulmonary infection.

222 lity worldwide, with higher risks to develop pulmonary infections, including Aspergillus infections.

223 The effect of the COX pathway on innate pulmonary inflammation induced by protease-containing fu

224 We evaluated associations between pulmonary inflammation, recovery of pathogen-specific CD

225 Pulmonary inflammatory responses lie under circadian con

226 ated chalcone and Nrf2 agonist, for targeted pulmonary inhalation aerosol drug delivery.

227 imaging manifestations of vaping-associated pulmonary injury, and the possibility of this condition

228 t CT is associated with clinical measures of pulmonary insufficiency and the risk of mortality.(C) RS

229 CO-RADS assesses the suspicion for pulmonary involvement of COVID-19 on a scale from 1 (ver

230 utrophil-attracting chemokines, and enhanced pulmonary leukocyte accumulation.

231 nclusions: The precise locations occupied by pulmonary macrophages were defined in nondiseased human

232 mic Force Microscopy, we show that mammalian pulmonary membranes suffer a structural transformation i

233 alterations in both pathways led to ACC with pulmonary metastases.

234 ing phases, with five patients showing focal pulmonary microthrombi.

235 TGF-beta signaling and EndMT occurs in mouse pulmonary microvascular ECs in vivo under hyperglycemic

236 dition of MC(TC)LUVA potentiated fetal human pulmonary microvascular endothelial cell interactions, i

237 However, how pulmonary Mtb infection causes cough remains undefined,

238 elioma, thymic epithelial tumours, and other pulmonary neuroendocrine neoplasms) and a COVID-19 diagn

239 inputs, emphysema, cardiomegaly, hernia, and pulmonary nodule detection had the highest fractional im

240 Rationale: The management of indeterminate pulmonary nodules (IPNs) remains challenging, resulting

241 r annual CT lung screening were analysed for pulmonary nodules (PN) detection and secondary lung canc

242 pithelial-endothelial barrier and increasing pulmonary oedema.

243 ed either adults or children presenting with pulmonary or extrapulmonary disease.

244 icacy testing of novel therapies, effects on pulmonary pathology and disease progression are monitore

245 These data indicate the onset of subclinical pulmonary perfusion abnormalities that could herald the

246 We evaluated regional pulmonary perfusion in Fontan patients (n = 5), healthy

247 ple is following the Fontan procedure, where pulmonary perfusion is passive, and heterogeneity may be

248 Many factors affect the distribution of pulmonary perfusion, which may be disrupted by cardiopul

249 lar resistance at rest, slope of increase in pulmonary pressure relative to cardiac output displayed

250 y VR was defined by the slope of increase in pulmonary pressure relative to cardiac output with exerc

251 ne the prevalence and correlates of abnormal pulmonary pressure, resistance, and compliance and their

252 use alterations in lung function, diminished pulmonary remodeling and regenerative capacity, and incr

253 to five groups (cardiovascular, hematology, pulmonary, renal, and endocrine).

254 in critically injured patients leads to the pulmonary sequestration of neutrophils (PMNs), which ser

255 s review focuses on the barriers that impact pulmonary siRNA delivery and successful recent approache

256 er a conditional role for the endodermal and pulmonary specifying TF GATA6 in lung adenocarcinoma (LU

257 round In patients with cystic fibrosis (CF), pulmonary structures with high MRI T2 signal intensity r

258 work explores the potential for strategizing pulmonary surfactant (PS) for drug delivery over the res

259 We synthesized pulmonary surfactant (PS)-biomimetic liposomes encapsula

260 as the cause of this outbreak of hantavirus pulmonary syndrome and to reconstruct person-to-person t

261 In the pulmonary system, T(RM) are identified through S1P antag

262 sts could improve diagnosis of both EPTB and pulmonary TB (PTB) and timely initiation of anti-TB ther

263 ncoded from detailed interviews of 76 and 64 pulmonary TB patients in the 2 Indian cities of Mumbai a

264 Patients with isoniazid-resistant pulmonary TB were recruited and followed up for 24 month

265 ial in which individuals with smear-positive pulmonary TB with isoniazid resistance mediated by an in

266 after ART initiation in adults with HIV and pulmonary TB.

267 wed 14 044 household contacts of adults with pulmonary TB.

268 ve inpatients, 46 (39%) had culture-positive pulmonary TB.

269 urpose To assess the clinical feasibility of pulmonary three-dimensional ultrashort echo time (UTE) M

270 iated with a pro-thrombotic state (four with pulmonary thromboembolism), one of whom died; (iv) perip

271 lleagues reported the frequent occurrence of pulmonary thrombosis in a series of autopsies of patient

272 Pulmonary tuberculosis (PTB) is one of the major health

273 Clinically diagnosed pulmonary tuberculosis (PTB) patients lack microbiologic

274 in human necrotic, nonnecrotic, and cavitary pulmonary tuberculosis (TB) lesions.

275 Transcatheter pulmonary valve replacement (TPVR) is associated with a

276 Pulmonary vascular abnormalities such as vessel enlargem

277 rculation of white blood cells (WBCs) in the pulmonary vascular bed is crucial for an effective immun

278 In particular, pulmonary vascular engraftment of miR-210-positive inter

279 s the alveolar-capillary barrier, triggering pulmonary vascular leak thus inducing acute lung injury

280 llowed the time-course of the development of pulmonary vascular remodeling in PAH rats.

281 ad mean pulmonary artery pressure >25 mm Hg, pulmonary vascular resistance >240 dyn-sec/cm(-5) , and

282 1.8 mm Hg; p = 0.005) and tended to decrease pulmonary vascular resistance (-83 +/- 33 dynes; p = 0.0

283 Additionally, pulmonary vascular resistance (PVR) 2.2 to 3.0 WU, consi

284 by neointimal lesions, resulting in elevated pulmonary vascular resistance and right heart failure.

285 As compared to pulmonary vascular resistance at rest, slope of increase

286 ypoxia leads to pathologic remodeling of the pulmonary vasculature and pulmonary hypertension (PH).

287 cal pulmonary hypertension, a disease of the pulmonary vasculature that results in right heart failur

288 and improved venous thrombus resolution and pulmonary vaso-occlusions in End.TGFbetaRII-KO mice.

289 indings may be explained by impaired hypoxic pulmonary vasoconstriction in infected lung regions, no

290 tions are needed to reinforce awareness that pulmonary vasodilators are unlikely to benefit group 2/3

291 In conclusion, BPA and pulmonary vasodilators both improve 6MWD and hemodynamic

292 ising new nonthermal ablation technology for pulmonary vein (PV) isolation in patients with atrial fi

293 The accuracy of prediction in each pulmonary vein computed tomography image for NPV trigger

294 esonance (CMR)-detected atrial fibrosis plus pulmonary vein isolation (PVI).

295 l (35 W), whereas in the experimental group, pulmonary vein isolation was performed using high power

296 Electrically isolating the pulmonary veins from the left atrium by catheter ablatio

297 model demonstrates that the large amount of pulmonary venous admixture observed in patients with ear

298 Abnormal pulmonary VR was defined by the slope of increase in pul

299 ypic switch from synthetic to contractile in pulmonary VSMCs.

300 asure of pulmonary disease severity on CXRs (pulmonary x-ray severity (PXS) score), using weakly-supe